Xxrobxxdo Xxarmxxusaxxnc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Xxrobxxdo Xxarmxxusaxxnc Pharmaceutical Import Records from India — 7 Products, $3.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Xxrobxxdo Xxarmxxusaxxnc — Pharmaceutical Importer Profile (2026) | 7 Products, $3.1M Trade | TransData Nexus

Xxrobxxdo Xxarmxxusaxxnc

Pharmaceutical Importer · United States · CNS & Psychiatric Focus · $3.1M Total Trade · DGFT Verified

Xxrobxxdo Xxarmxxusaxxnc is a pharmaceutical importer based in United States with a total trade value of $3.1M across 7 products in 4 therapeutic categories. Based on 71 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Xxrobxxdo Xxarmxxusaxxnc sources from 2 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 97.6% of imports.

Xxrobxxdo Xxarmxxusaxxnc — Import Portfolio & Supplier Network

Xxrobxxdo Xxarmxxusaxxnc import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Xxrobxxdo Xxarmxxusaxxnc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$13.2M	335	97.6%
Apl Healthcare Limited	$318.7K	9	2.4%

Xxrobxxdo Xxarmxxusaxxnc sources from 2 verified Indian suppliers across .

What Formulations Does Xxrobxxdo Xxarmxxusaxxnc Import?

Formulation	Value	Ships
Tamsulosin hydrochloride capsules 0.4 MG	$1.4M	32
Glipizide extended-release tablets 5 MG	$547.5K	12
Divalproex sodium extended-release	$512.1K	13
Pantoprazole tablets 40 MG 1000's	$489.5K	10
Omeprazole delayed-release capsules 40MG	$361.6K	8
Sulfamethoxazole / trimethoprim	$359.0K	11
Metformin tablets 500 MG 1000's	$300.0K	6
Pantoprazole tablets 40 MG 90's	$283.2K	6
Amlodipine besylate and benazepril	$252.9K	6
Montelukast sodium tablets 10 MG	$240.7K	5
Alprazolam tablets 0.5 MG 1000's	$224.4K	5
Alprazolam tablets 0.5 MG 100's	$207.7K	6
Clozapine tablets 100 MG 500's	$200.0K	4
Pantoprazole tablets 20 MG 90's	$193.8K	4
Metformin 1000 MG tablets 1000's	$178.4K	4

Xxrobxxdo Xxarmxxusaxxnc imports 137 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Alprazolam	CNS & Psychiatric	$1.4M	32	8.6%	4
2	Sulfamethoxazole	Advanced Antibiotics	$427.3K	11	2.2%	10
3	Trimethoprim	Advanced Antibiotics	$427.3K	11	1.6%	12
4	Simvastatin	Cardiovascular	$350.0K	7	0.3%	5
5	Montelukast	Respiratory	$250.0K	5	0.1%	16
6	Moxifloxacin	Advanced Antibiotics	$150.0K	3	0.5%	15
7	Amiodarone	Cardiovascular	$100.0K	2	0.1%	11

Xxrobxxdo Xxarmxxusaxxnc imports 7 pharmaceutical products across 4 categories into United States totaling $3.1M.

Xxrobxxdo Xxarmxxusaxxnc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Xxrobxxdo Xxarmxxusaxxnc is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company has established a significant presence in the U.S. pharmaceutical distribution network by importing a diverse range of pharmaceutical products. While specific details about its headquarters and parent company are not publicly disclosed, Xxrobxxdo Xxarmxxusaxxnc plays a pivotal role in ensuring the availability of various pharmaceutical products within the U.S. market.

2Distribution Network

Xxrobxxdo Xxarmxxusaxxnc's distribution network encompasses multiple warehouse locations across the United States, strategically positioned to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a substantial volume of imports and coordinate effectively with domestic distribution channels. This extensive network ensures comprehensive geographic coverage, meeting the pharmaceutical needs of various regions within the United States.

3Industry Role

In the U.S. pharmaceutical supply chain, Xxrobxxdo Xxarmxxusaxxnc functions primarily as a pharmaceutical importer and buyer. By sourcing finished pharmaceutical formulations from international suppliers, the company acts as an intermediary between foreign manufacturers and the U.S. market. This role is crucial in diversifying the pharmaceutical product offerings available to U.S. consumers and healthcare providers, thereby enhancing market competition and access to a broader range of medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Xxrobxxdo Xxarmxxusaxxnc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Xxrobxxdo Xxarmxxusaxxnc exhibits a high degree of sourcing concentration, with 97.6% of its imports originating from AUROBINDO PHARMA LIMITED, accounting for $13.2 million across 335 shipments. This significant reliance on a single supplier indicates a strategic choice to leverage AUROBINDO's extensive product portfolio and established manufacturing capabilities. However, such concentration also introduces potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges faced by AUROBINDO. The stability of this relationship is evidenced by the consistent volume of shipments over the years, suggesting a strong and reliable partnership.

2Supply Chain Resilience

The resilience of Xxrobxxdo Xxarmxxusaxxnc's supply chain is closely tied to the stability and reliability of AUROBINDO PHARMA LIMITED. The company's limited engagement with other suppliers, such as APL HEALTHCARE LIMITED, which accounts for only 2.4% of imports, indicates a lack of diversified sourcing strategies. This limited diversification may expose Xxrobxxdo Xxarmxxusaxxnc to supply chain vulnerabilities in the event of disruptions affecting AUROBINDO. Additionally, the company's focus on a narrow range of formulations, with 137 unique formulations imported, suggests a specialized product strategy that may limit flexibility in adapting to market changes.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring they meet the necessary standards before entering the U.S. market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are stringent. Importers must ensure that their products are approved by the FDA and comply with the agency's regulations. Good Manufacturing Practice (GMP) certification is a critical component of this compliance. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must verify that their suppliers hold valid GMP certifications from recognized authorities to ensure product quality and safety.

Xxrobxxdo Xxarmxxusaxxnc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Xxrobxxdo Xxarmxxusaxxnc's product strategy focuses on specific therapeutic areas, including Central Nervous System (CNS) & Psychiatric disorders, Advanced Antibiotics, and Cardiovascular conditions. The company's imports in these categories are substantial, with CNS & Psychiatric products accounting for 45.5% of imports, Advanced Antibiotics 32.1%, and Cardiovascular 14.4%. This focus aligns with market demand for treatments in these areas, driven by factors such as the prevalence of mental health conditions, antibiotic resistance, and cardiovascular diseases in the U.S. population.

2Sourcing Profile

Xxrobxxdo Xxarmxxusaxxnc's sourcing strategy emphasizes generic drug formulations, particularly in the CNS & Psychiatric, Advanced Antibiotics, and Cardiovascular categories. The company's imports from India, primarily sourced from AUROBINDO PHARMA LIMITED, reflect a preference for established manufacturers with a broad product portfolio. This approach aims to ensure a consistent supply of high-quality generic medications to meet the therapeutic needs of the U.S. market.

3Market Positioning

Based on its product mix, Xxrobxxdo Xxarmxxusaxxnc serves multiple segments of the U.S. pharmaceutical market. The company's focus on CNS & Psychiatric, Advanced Antibiotics, and Cardiovascular products positions it to supply retail pharmacies, hospitals, and healthcare providers with essential medications. By importing generic formulations, Xxrobxxdo Xxarmxxusaxxnc contributes to the availability of cost-effective treatment options across these therapeutic areas.

Seller's Guide — How to Become a Supplier to Xxrobxxdo Xxarmxxusaxxnc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Xxrobxxdo Xxarmxxusaxxnc, particularly in the therapeutic categories where the company imports products. The company's limited diversification in suppliers suggests potential gaps that new entrants could fill, especially if they can offer competitive pricing, high-quality products, and reliable supply chains. Establishing partnerships with Xxrobxxdo Xxarmxxusaxxnc could provide Indian exporters with access to the U.S. market and enhance their global presence.

2Requirements & Qualifications

Indian exporters seeking to supply Xxrobxxdo Xxarmxxusaxxnc and the U.S. market must adhere to FDA regulations, including obtaining necessary import licenses and ensuring compliance with GMP standards recognized by the FDA. Products must undergo batch testing, meet stability requirements, and have labeling in English that complies with FDA guidelines. Additionally, exporters must implement serialization mandates to facilitate traceability and prevent counterfeit products.

3How to Approach

Frequently Asked Questions — Xxrobxxdo Xxarmxxusaxxnc

What products does Xxrobxxdo Xxarmxxusaxxnc import from India?

Xxrobxxdo Xxarmxxusaxxnc imports 7 pharmaceutical products across 4 categories. Top imports: Alprazolam ($1.4M), Sulfamethoxazole ($427.3K), Trimethoprim ($427.3K), Simvastatin ($350.0K), Montelukast ($250.0K).

Who supplies pharmaceuticals to Xxrobxxdo Xxarmxxusaxxnc from India?

Xxrobxxdo Xxarmxxusaxxnc sources from 2 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (97.6% of imports, $13.2M).

What is Xxrobxxdo Xxarmxxusaxxnc's total pharmaceutical import value?

Xxrobxxdo Xxarmxxusaxxnc's total pharmaceutical import value from India is $3.1M, based on 71 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Xxrobxxdo Xxarmxxusaxxnc focus on?

Xxrobxxdo Xxarmxxusaxxnc imports across 4 categories. The largest: CNS & Psychiatric (45.5%), Advanced Antibiotics (32.1%), Cardiovascular (14.4%).

Get Full Xxrobxxdo Xxarmxxusaxxnc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.